Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · Real-Time Price · USD
15.28
-0.56 (-3.54%)
At close: May 15, 2026, 4:00 PM EDT
15.20
-0.08 (-0.52%)
After-hours: May 15, 2026, 7:42 PM EDT
Aurinia Pharmaceuticals Revenue
Aurinia Pharmaceuticals had revenue of $77.71M in the quarter ending March 31, 2026, with 24.40% growth. This brings the company's revenue in the last twelve months to $298.30M, up 20.62% year-over-year. In the year 2025, Aurinia Pharmaceuticals had annual revenue of $283.06M with 20.38% growth.
Revenue (ttm)
$298.30M
Revenue Growth
+20.62%
P/S Ratio
6.59
Revenue / Employee
$2,330,430
Employees
128
Market Cap
1.97B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 283.06M | 47.92M | 20.38% |
| Dec 31, 2024 | 235.13M | 59.62M | 33.97% |
| Dec 31, 2023 | 175.51M | 41.48M | 30.95% |
| Dec 31, 2022 | 134.03M | 88.43M | 193.89% |
| Dec 31, 2021 | 45.61M | -4.51M | -9.00% |
| Dec 31, 2020 | 50.12M | 49.80M | 15,660.38% |
| Dec 31, 2019 | 318.00K | -145.00K | -31.32% |
| Dec 31, 2018 | 463.00K | 45.00K | 10.77% |
| Dec 31, 2017 | 418.00K | 245.00K | 141.62% |
| Dec 31, 2016 | 173.00K | -1.00M | -85.29% |
| Dec 31, 2005 | 1.18M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 2.18B |
| ADMA Biologics | 509.86M |
| Ascentage Pharma Group International | 82.08M |
| Mesoblast | 65.38M |
| Ocular Therapeutix | 52.04M |
| Stoke Therapeutics | 32.08M |
| Generate Biomedicines | 30.30M |
AUPH News
- 9 days ago - Aurinia Pharmaceuticals reports Q1 EPS 25c, consensus 20c - TheFly
- 9 days ago - Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress - Business Wire
- 6 weeks ago - Kezar Life Sciences takeover valuation ‘makes sense,’ says Jefferies - TheFly
- 6 weeks ago - Aurinia to acquire Kezar Life Sciences for $6.955 in cash per share plus CVR - TheFly
- 6 weeks ago - Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right - Business Wire
- 7 weeks ago - MKT Capital ‘applauds’ Aurinia’s management transition - TheFly
- 7 weeks ago - MKT Capital Applauds Aurinia Pharmaceuticals' Management Transition - Business Wire
- 7 weeks ago - Aurinia Pharmaceuticals announces Tang to succeed Greenleaf as CEO - TheFly